🔍 Why It Matters
☑️ 20% of HR+/HER2- EBC patients relapse despite adjuvant C-ET.
✅ Existing tools (e.g., 21-gene, 70-gene) guide chemo decisions but fail to pinpoint high-risk patients after C-ET.
#Onco404 #Cancer #Kanser #BreastCancer #MemeKanseri #OncotypeDX #MammaPrint #Prosigna #OncSky #MedSky
1
0
1
0